Altimmune announces data presentation on alt-801, its balanced and long-acting glp-1/glucagon receptor dual agonist for nash, at the digital international liver congress™ 2020

Gaithersburg, md., aug. 26, 2020 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, today announced a preclinical data presentation on alt-801, its balanced and long-acting glp-1/glucagon receptor dual agonist under development for nash, at the digital international liver congress™ 2020, the 55th annual meeting of the european association for the study of the liver (easl), to be held virtually from august 27, 2020 to august 29, 2020.
ALT Ratings Summary
ALT Quant Ranking